{
    "nctId": "NCT05145907",
    "briefTitle": "Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors",
    "officialTitle": "A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerability and Preliminary Efficacy of TJ107 Combine With Pembrolizumab Injection in Patients With Locally Advanced or Metastatic Solid Tumors",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 133,
    "primaryOutcomeMeasure": "The rate of Adverse events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female patients aged over 18 years (inclusive);\n* ECOG score: 0 - 2 points\n* Patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors, including TNBC and HNSCC\n* No previous treatment with CPI\n* Agreement to provide a previously archived tumor tissue specimen or biopsy to collect tumor lesion tissue\n* Subject has at least 1 measurable lesion as defined by RECIST V1.1\n* Expected survival \u2265 6 months\n* Adequate organ function\n* Males of childbearing potential or females of childbearing potential must use highly effective contraceptive methods during the trial and continuing for 6 months after the last dose\n* The subject voluntarily joined the study and signed an informed consent form\n\nExclusion Criteria:\n\n* Pregnant or lactating women;\n* Prior cell therapy;\n* Received systemic anti-tumor therapy within 2 weeks or 5 half-lives of the treatment agent (whichever is shorter) before the start of treatment;\n* Previous or current presence of two or more primary tumors\n* Patients with active autoimmune diseases\n* Have received systemic treatment with corticosteroids (10 mg prednisone equivalent daily) or other immunosuppressive agents for more than 7 days within 2 weeks before the start of treatment\n* Received investigational drugs within 2 weeks before the start of treatment;\n* Major surgery or serious trauma within 4 weeks before the start of treatment;\n* Patients with symptomatic central nervous system (CNS) metastasis\n* Active viral infectious disease requiring systemic treatment at screening:\n* Known serious hypersensitivity history\n* Uncontrolled pleural effusion, ascites, or pericardial effusion at screening;\n* Presence or history of active interstitial lung disease;\n* Patients with hypertension that cannot be well controlled with medical therapy.\n* Presence of clinically significant cardiovascular disease\n* Deep venous thrombosis within 6 months before the start of treatment\n* Thrombolytic therapy within 10 days prior to the start of treatment\n* Any active infection requiring intravenous anti-infective therapy before the start of treatment\n* Had toxicity not resolved to \u2264 Grade 1 (CTCAE 5.0) from previous anticancer therapy\n* Known or suspected inability to comply with the study protocol",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}